ID: ALA327105

Max Phase: Preclinical

Molecular Formula: C12H15N5O3

Molecular Weight: 277.28

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  C[C@@H](O)C1=C[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C12H15N5O3/c1-5(18)6-2-7(10(20)9(6)19)17-4-16-8-11(13)14-3-15-12(8)17/h2-5,7,9-10,18-20H,1H3,(H2,13,14,15)/t5-,7-,9-,10+/m1/s1

Standard InChI Key:  CDKUWLLYHVOVCD-PXMQNUKVSA-N

Associated Targets(Human)

KATO III stomach cancer cell line (114 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AHCY Tchem Adenosylhomocysteinase (906 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEL (6614 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HeLa (62764 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MT4 (17854 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Vero (26788 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium berghei (192651 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADA Adenosine deaminase (739 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ahcy Adenosylhomocysteinase (45 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDCK (10148 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Adenosylhomocysteinase (17 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 277.28Molecular Weight (Monoisotopic): 277.1175AlogP: -1.01#Rotatable Bonds: 2
Polar Surface Area: 130.31Molecular Species: NEUTRALHBA: 8HBD: 4
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.08CX Basic pKa: 4.10CX LogP: -1.77CX LogD: -1.77
Aromatic Rings: 2Heavy Atoms: 20QED Weighted: 0.52Np Likeness Score: 0.63

References

1. Shuto S, Obara T, Toriya M, Hosoya M, Snoeck R, Andrei G, Balzarini J, De Clercq E..  (1992)  New neplanocin analogues. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents.,  35  (2): [PMID:1732550] [10.1021/jm00080a018]
2. Shuto S, Obara T, Kosugi Y, Saito Y, Toriya M, Yaginuma S, Shigeta S, Matsuda A.  (1994)  New neplanocin analogues. III. 6R-configuration is essential for the antiviral activity of 6-C-methyl-3-deazaneplanocin a's,  (4): [10.1016/S0960-894X(01)80163-3]
3. Shuto S, Minakawa N, Niizuma S, Kim HS, Wataya Y, Matsuda A..  (2002)  New neplanocin analogues. 12. Alternative synthesis and antimalarial effect of (6'R)-6'-C-methylneplanocin A, a potent AdoHcy hydrolase inhibitor.,  45  (3): [PMID:11806727] [10.1021/jm010374i]
4. Singh K, Joshi P, Mahar R, Baranwal P, Shukla SK, Tripathi R, Tripathi RP..  (2018)  Synthesis and antiplasmodial activity of purine-based C-nucleoside analogues.,  (7): [PMID:30109012] [10.1039/C8MD00098K]

Source